These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20019584)

  • 1. Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.
    Zhu W; Zhu DS; Madan RA; Gulley JL; Figg WD; Dahut WL
    Am J Ther; 2010; 17(2):176-81. PubMed ID: 20019584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for targeting the androgen receptor axis in prostate cancer.
    Carver BS
    Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches to targeting the androgen receptor pathway in prostate cancer.
    Velho PI; Bastos DA; Antonarakis ES
    Clin Adv Hematol Oncol; 2021 Apr; 19(4):228-240. PubMed ID: 33989272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
    Isaacsson Velho P; Carducci MA
    Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
    McCarty MF; Hejazi J; Rastmanesh R
    Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
    Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
    Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer.
    Shen HC; Balk SP
    Cancer Cell; 2009 Jun; 15(6):461-3. PubMed ID: 19477425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical update on the strategies towards modulators targeting androgen receptors.
    Luan H; Xu P; Meng Y; Li Z; Bian J
    Bioorg Med Chem; 2020 Jul; 28(13):115554. PubMed ID: 32546299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel hormonal approaches in prostate cancer.
    Friedlander TW; Ryan CJ
    Curr Oncol Rep; 2009 May; 11(3):227-34. PubMed ID: 19336015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications.
    Aurilio G; Cimadamore A; Mazzucchelli R; Lopez-Beltran A; Verri E; Scarpelli M; Massari F; Cheng L; Santoni M; Montironi R
    Cells; 2020 Dec; 9(12):. PubMed ID: 33321757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
    Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
    FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
    Biron E; Bédard F
    J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
    Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
    Scher HI; Buchanan G; Gerald W; Butler LM; Tilley WD
    Endocr Relat Cancer; 2004 Sep; 11(3):459-76. PubMed ID: 15369448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer.
    Westaby D; Fenor de La Maza MLD; Paschalis A; Jimenez-Vacas JM; Welti J; de Bono J; Sharp A
    Annu Rev Pharmacol Toxicol; 2022 Jan; 62():131-153. PubMed ID: 34449248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G; Baniahmad A
    Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.